Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Moyle

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology|July 11, 2016
N2 and P3 modulation during partial inhibition in a modified go/nogo taskAn T Nguyen, Jonson J Moyle, Allison M Fox
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1993
Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virusM R Nelson, G J Moyle, B G Gazzard
HIV Medicine|February 24, 2006
Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophyG J Moyle, S Brown, L Lysakova, et al.
Seminars in Speech and Language|August 27, 2025
What of It? Coding the Unmarked Of-Preposition in Language Samples from Young AAE SpeakersDenise A Finneran, Maura J Moyle, Alaina Nash, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|September 1, 1995
AIDS: clinical and scientific issues past, present and futureA G Dalgleish, G J Moyle, P Easterbrook, et al.
Antiviral Therapy|August 1, 1996
Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study GroupG J Moyle, M Walker, R Harris, et al.
The Quarterly Journal of Medicine|March 1, 1993
The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)G J Moyle, M R Nelson, D Hawkins, et al.
Clinical Drug Investigation|February 22, 2014
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infectionGraeme J Moyle, Hélène Hardy, Awny Farajallah, et al.
Drugs|April 8, 1998
Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and useG J Moyle, B G Gazzard, D A Cooper, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 7, 2003
A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophyG J Moyle, C Baldwin, B Langroudi, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology|July 11, 2016
N2 and P3 modulation during partial inhibition in a modified go/nogo taskAn T Nguyen, Jonson J Moyle, Allison M Fox
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1993
Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virusM R Nelson, G J Moyle, B G Gazzard
HIV Medicine|February 24, 2006
Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophyG J Moyle, S Brown, L Lysakova, et al.
Seminars in Speech and Language|August 27, 2025
What of It? Coding the Unmarked Of-Preposition in Language Samples from Young AAE SpeakersDenise A Finneran, Maura J Moyle, Alaina Nash, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|September 1, 1995
AIDS: clinical and scientific issues past, present and futureA G Dalgleish, G J Moyle, P Easterbrook, et al.
Antiviral Therapy|August 1, 1996
Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study GroupG J Moyle, M Walker, R Harris, et al.
The Quarterly Journal of Medicine|March 1, 1993
The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)G J Moyle, M R Nelson, D Hawkins, et al.
Clinical Drug Investigation|February 22, 2014
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infectionGraeme J Moyle, Hélène Hardy, Awny Farajallah, et al.
Drugs|April 8, 1998
Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and useG J Moyle, B G Gazzard, D A Cooper, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 7, 2003
A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophyG J Moyle, C Baldwin, B Langroudi, et al.
Pageof 8